| __timestamp | Eli Lilly and Company | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 9335772 |
| Thursday, January 1, 2015 | 6533000000 | 12390000 |
| Friday, January 1, 2016 | 6452000000 | 25602000 |
| Sunday, January 1, 2017 | 6588100000 | 21262000 |
| Monday, January 1, 2018 | 5975100000 | 28430000 |
| Tuesday, January 1, 2019 | 6213800000 | 40849000 |
| Wednesday, January 1, 2020 | 6121200000 | 60210000 |
| Friday, January 1, 2021 | 6431600000 | 83664000 |
| Saturday, January 1, 2022 | 6440400000 | 104097000 |
| Sunday, January 1, 2023 | 6941200000 | 106916000 |
| Monday, January 1, 2024 | 8593800000 |
Data in motion
In the world of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. This chart provides a fascinating comparison between Eli Lilly and Company, a pharmaceutical giant, and Iovance Biotherapeutics, Inc., a rising star in the biotech sector, from 2014 to 2023.
Eli Lilly's SG&A expenses have shown a steady trend, averaging around $6.4 billion annually, with a notable peak in 2023, marking a 16% increase from its lowest point in 2018. In contrast, Iovance Biotherapeutics, Inc. has experienced a dramatic rise in SG&A expenses, growing over tenfold from 2014 to 2023. This reflects Iovance's aggressive expansion and investment in its operations.
This comparison highlights the different growth strategies of established and emerging companies in the healthcare industry, offering insights into their financial management and market positioning.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Bristol-Myers Squibb Company
Eli Lilly and Company or Sanofi: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Eli Lilly and Company and Corcept Therapeutics Incorporated
Eli Lilly and Company and Novavax, Inc.: SG&A Spending Patterns Compared
AbbVie Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Bristol-Myers Squibb Company vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Breaking Down SG&A Expenses: Opthea Limited vs Iovance Biotherapeutics, Inc.
Veracyte, Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Iovance Biotherapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Soleno Therapeutics, Inc. or Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Iovance Biotherapeutics, Inc. or Dynavax Technologies Corporation